Waystar Considers Sale Amid Stock Decline, Sources Reveal

Healthcare software provider Waystar is reportedly evaluating strategic options, including a potential sale, according to sources familiar with the matter. This move comes just two years after the company went public in New York. The Lehi, Utah, and Louisville, Kentucky-based firm has enlisted investment bank Evercore to advise on the process, which is still in its early stages. The sources, who requested anonymity due to the confidential nature of the information, indicated that plans could change and a sale may not proceed.

Market Challenges and Strategic Positioning

Waystar, which provides technology solutions to automate and manage administrative tasks for hospitals and doctors, has been trying to position itself as a tech company rather than a service-oriented business. This strategy was aimed at securing higher valuations typical for technology firms. However, Waystar has seen its market value drop to approximately $4.8 billion, following a 24% decrease in its share price this year. This decline is part of a broader downturn affecting the software sector.

The company's initial public offering in 2024 was supported by major backers including EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital. These investors hoped to capitalize on the rising demand for healthcare software solutions. EQT remains the largest shareholder with a 13% stake, followed by CPPIB with 10% and BlackRock Institutional Trust Company with 8%.

Investor Sentiments and Market Conditions

Waystar's share price initially rose from $20 to a peak of $45 in 2025, as investors were optimistic about its growth prospects. However, concerns over potential disruptions from advancements in artificial intelligence have since pressured the stock. A July report by Morgan Stanley analysts highlighted these investor apprehensions.

The exploration of a sale could serve as a barometer for investor interest in software companies amid current market conditions. Waystar's potential sale represents a significant decision for its stakeholders, as they weigh the benefits of remaining publicly traded against a return to private ownership.

Comments from Key Stakeholders

Waystar has declined to comment on the matter, while Evercore has not yet responded to requests for comment. Similarly, EQT and BlackRock have refrained from commenting, and CPPIB has not immediately provided a response.

Waystar was created in 2017 through the merger of healthcare revenue management firms Zirmed and Navicure. Its trajectory has reflected the broader challenges and opportunities faced by companies in the healthcare technology sector, as they navigate evolving investor expectations and market dynamics.